Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, aged 60 to 64 years.~* Healthy.~Exclusion Criteria:~* Previous vaccination with any licensed or experimental pneumococcal vaccine.~* History of severe adverse reaction associated with a vaccine.~* Immunodeficiency.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Group 1.1 (Type: EXPERIMENTAL): Group 1.1 = 13vPnC then 13vPnC
- Group 1.2 (Type: EXPERIMENTAL): Group 1.2 = 13vPnC then 23vPS
- Group 2 (Type: EXPERIMENTAL): Group 2 = 23vPS then 13vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).